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SPLAGCMIC VASODILATATION AFTER VASOPRESSIN INWIBITION IN 
AREA-POSTBEMA LESIQNED CONGESTIVE HEART FAILURE DOCS 
Werk S. Brownfield. Stephen H. 
Cardiology Sect&n. University of Wisconsin, Xadi 
Nellis, 
son, WI 
Despite the high density of vasopressin Vi receptors in 
mesenteric vasculature. Vi-receptor inhibition (VBI) in 
congestive heart failure (CHF) is not associated with 
increased splanchnic blood flow. Splanchnic vasodilatation 
does occur with VBI in CHF after adrenergic blockade. 
Since vasopressin exerts an inhibitory influence upon the 
sympathetic nervous system through Vi receptors of the area 
postrema (AP) of the hindbrain, the role of the AP in the 
response of regional circulations to VBI was determined. 
CHF ~5s produced in dogs by tricuspid avulsion and pro- 
gressive pulmonary artery constriction. Following the 
development of CHF, 5 dogs underwent AP ablation while 3 
dogs underwent sham-ablation. VP1 in the sham-ablated dogs 
caused an increase in LV dF/dt and CO, whereas in the AP- 
ablated dogs a decrease iir mean A0 pressure occurred. 
Regional blood flows were determined before and after VBI 
by microsphere technique: 
Small Intestine Pencreas 
Pre-VRI Post-VRI Pre-VRI Post--4R1 
Sham-ablated 5026 5826 200234 184216 
AP-ablated 3124 !%$l?+ 147*17 196*29* 
(d/l00 ,&min; +p<O.O5 versu6 pre-VW; &a ) 
Thus, splanchnic blood flow increased after VBI in the 
AP-ablated but not the sham-ablated CHF dogs, suggesting 
that the interaction of vasopressin with the AP abolishes 
the decrease in peripheral mesenteric Vi vasoconstriction 
after VRI. 
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INFLUENCE OF DRUGS ON THE MYDCARDIAL UPTAKE OF ‘f%MlBG. 
Daniel Fagret, Gerald Vanzetto, Jacques 
rnard Denis. CH3, Grenoble, France 
Machecourt, 
%MlBG (metaiodobenzylguanidine), a norepinephrfne analog, has been 
recently proposed for the study of myocardial catecholamine metabolism. 
The aim of our study was to evaluate the influence of drugs on the 
myocardial f23lMlBG fixation. 4 mCI of 12%MIBG were injected to 97 
patients (10 controls without treatment, and 87 with different treatments, Cf 
Table) and a left anterior oblique 45O (LAO) cardiac image was obtained 4 h 
post injection. Regions of interest (Rol) were drawn around the healthy left 
ventricule (LV) and around a mediastinal area. The LV to mediastinal Rol 
activity per pixel ratio were calculated to appreciate the myocardial uptake of 
12%MIBG. The results were as follows : 
l Control n-10 1.78?s 0.18 I 
* Cardiac glycosides 
Except heparin, drugs decrease the myocardial fixation of 123i-MlBG, 
especially cardiac glycosides and labetalol, as these drugs decrease, in 
animal, the uptake 0. 3Hnorepinephrine. 
In: 
10 Drugs influence the myocardial uptake of 1*31-MIBG, 
2- Any interpretation of ‘2%MIBG scintigraphic image should take into 
account the drugs tha: have been administered to the patients. 
TECHNEllUM99m ANIIMYGSIN IMAGING IN A 
Patrick A. Egbe, James Coromilas, Roxanne A. 
Robert A. Vaccarfno, Lynne L. Johnson, Columbia 
Rodney, David W. Setdin, 
Iridium-111 antimyosin(ln-111AM) (RllDlO, Centocor)has been used to 
detect myocardial necrosis in experimental animals, and in patients. 
However, clinical application of In-l 11AM is limited by: slow blood clearance 
with optimal imaging time 24-48 hrs post injection, long half life of In-111 
limiting dosimetry, and hepatic uptake interfering 
vfsualiiation. Technetium-99m (Tc-99m). a more optimal 
been bound to antimyosin Fab’ using the RP-1 technique 
(Centocor). Two hour balloon catheter coronary artery occlusions.were 
performed in 8 dogs. Tc-99m antimyosin was prepared using 19.6 mCi 
(mean dose) of Tc99m and injected 24-72 hrs post infarct. Planar imaging 
was performed 4-20 hrs post injection. Blood clearance samples were 
obtained. The animals were sacrificed and hear& stained with triphenyl 
tetrazolium chlor clearance data were fit to a biexponential 
curve: the first T112 = 29.5 f 7.6 min, the second slow 
component Tl12 Planar scans showed focal myocardial 
uptake in 6 of 8 dogs, which corresponded to areas of infarct on TTC 
staining. Two dogs had negative scans and no infarct on TTC staining. Focal 
myocardial uptake was identtfied as early as 4 
uptake wa 10 hrs post injection. 
the gallbla 
In summary, in a canine Technetium99m antimyosin (RP-1 ligand 
technique) has eeriy upla injection into areas of myoca necrosis, 
and no apparent hepatic ; therefore it may be a promi agent to 
detect acute myocardial infarction in patients. 
RAPID IMAGING OF CORONARY THROMBI BY TC-99m 
LABELED ANTIFIBRIN MONOCK)NAL ANTIBODY Peter Funk 
MD Jamshid Maddahi, MD, FACC, Pierre Chouraqui, MD, Juliana 
ITi& Carey Th omas, Harvey Berger, MD, FACC, Daniel Berman, 
MD, FACC, William Ganz, MD, FACC. UCLA School of Medicine 
and Cedars-Sinai Medical Center, Los Angeles, CA 
The feasibility of coronary thrombus (THR) imaging by technetium- 
99m labeled antifibrin monoclonal antibody (Tc-T2Gls) was evaluated 
in 37 dog experiments (EXPs) in which occlusive coronary THR 
(weight = 13&13 mg) were induced by uanscatotid insertion of copper 
coils. In EXP 1 (N=4), an additional occlusive THR was induced iq 
the femoral artery and then IO-12 mCi of Tc-Tz( 1s was administered 
intravenously. In EXP 2 (N=lS), 1 mCi of Tc ‘s2Gls was injected 
into the coronary artery proximal to THR. In E&P 3 (N=9) occlusive 
coronary THR were partially lysed by streptokinase before 
itrtracoronary injection of 1 mCi of Tc-T2Gls. In Exp 4 (N=4), 1 mCi 
of In-l 11 labeled control non specific antibody an I 1 mCi of Tc- 
T2Gls were sequentially injected in the coronary artery. Serial in vivo 
images were obtained for up to 2 hours. Ex vivo THR weights and 
THR to blood specific radioactivity ratios (SRR) were determined after 
sacrifice. In EXP 1, ex vivo THR to blood SRR’s were similar for 
femoral and coronary THR (6 f 3 vs 4 f 2 respectively, p= NS). 
However, unlike femoral artery THR, coronary THR were not 
visualir ti due to marked ventricular blood pool background. In EXP’s 
2 and 3, intracoronary injection of Tc-T2Gls significantly increased 
THR to blood SRR (430&657 and 143f198, respectively). As a result, 
92 % of THR were ranidlv visualized in vivo and remained wsitive 
until the end of the shady. ‘in EXP 4, THR were distinctly po&ve by 
Tc-T2Gls while thev were not visualized bv the control non sneciflc 
antibody. Ex vivo mkasurements showed thit the THR uptake’of Tc- 
T2Gls was 538 times higher than that of the control antibody. In 
conclusion: 1) Tc-T2Gl s specifically binds to coronary THR in vivo, 
2) intravenous administration precludes visualization of coronary THR 
in vivo due to low THR to background ratio, however, 3) 
intracoronary injection of Tc-T2Gls allows successful, rapid 
visualization of totally and partially occlusive coronary thrombi. 
